DK1107744T3 - Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi - Google Patents

Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi

Info

Publication number
DK1107744T3
DK1107744T3 DK99942911T DK99942911T DK1107744T3 DK 1107744 T3 DK1107744 T3 DK 1107744T3 DK 99942911 T DK99942911 T DK 99942911T DK 99942911 T DK99942911 T DK 99942911T DK 1107744 T3 DK1107744 T3 DK 1107744T3
Authority
DK
Denmark
Prior art keywords
antagonists
treatment
substance
fibromyalgia
chronic fatigue
Prior art date
Application number
DK99942911T
Other languages
English (en)
Inventor
Wolfgang Mueller
Thomas Stratz
Lothar Faerber
Original Assignee
Wolfgang Mueller
Thomas Stratz
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818467.4A external-priority patent/GB9818467D0/en
Priority claimed from GBGB9826692.7A external-priority patent/GB9826692D0/en
Application filed by Wolfgang Mueller, Thomas Stratz, Novartis Ag filed Critical Wolfgang Mueller
Application granted granted Critical
Publication of DK1107744T3 publication Critical patent/DK1107744T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99942911T 1998-08-25 1999-08-24 Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi DK1107744T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818467.4A GB9818467D0 (en) 1998-08-25 1998-08-25 Organic compounds
GBGB9826692.7A GB9826692D0 (en) 1998-12-04 1998-12-04 Organic compounds
PCT/EP1999/006215 WO2000010545A2 (en) 1998-08-25 1999-08-24 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
DK1107744T3 true DK1107744T3 (da) 2003-07-28

Family

ID=26314255

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99942911T DK1107744T3 (da) 1998-08-25 1999-08-24 Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi

Country Status (14)

Country Link
US (5) US20030092735A1 (da)
EP (1) EP1107744B1 (da)
JP (1) JP4510290B2 (da)
CN (1) CN1216598C (da)
AT (1) ATE238044T1 (da)
AU (1) AU5624599A (da)
BR (1) BR9913201A (da)
CA (1) CA2339628C (da)
DE (1) DE69907220T2 (da)
DK (1) DK1107744T3 (da)
ES (1) ES2198948T3 (da)
PT (1) PT1107744E (da)
TW (1) TW200529847A (da)
WO (1) WO2000010545A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274604B1 (en) 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7295500B2 (en) * 2002-09-30 2007-11-13 Nec Corporation Recording condition setting method and information recorder using same
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
CN101668527A (zh) * 2007-02-23 2010-03-10 阿韦拉制药股份有限公司 药物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
AU648317B2 (en) * 1990-06-01 1994-04-21 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
JP3925662B2 (ja) * 1995-01-12 2007-06-06 グラクソ，グループ，リミテッド タキキニンアンタゴニスト活性を有するピペリジン誘導体
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
AU2611297A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Bisindoles for treating pain or nociception
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
WO1998024438A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia

Also Published As

Publication number Publication date
US20100055176A1 (en) 2010-03-04
CN1348372A (zh) 2002-05-08
US20030092735A1 (en) 2003-05-15
CN1216598C (zh) 2005-08-31
CA2339628C (en) 2008-06-03
JP4510290B2 (ja) 2010-07-21
EP1107744B1 (en) 2003-04-23
DE69907220D1 (de) 2003-05-28
BR9913201A (pt) 2001-05-08
DE69907220T2 (de) 2004-02-05
TW200529847A (en) 2005-09-16
WO2000010545A3 (en) 2000-08-10
US20080161329A1 (en) 2008-07-03
WO2000010545A2 (en) 2000-03-02
PT1107744E (pt) 2003-08-29
US7713984B2 (en) 2010-05-11
US20050096334A1 (en) 2005-05-05
CA2339628A1 (en) 2000-03-02
EP1107744A2 (en) 2001-06-20
JP2002523363A (ja) 2002-07-30
US20070155759A1 (en) 2007-07-05
ATE238044T1 (de) 2003-05-15
ES2198948T3 (es) 2004-02-01
AU5624599A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
DK1076644T3 (da) N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
EA200200291A1 (ru) Производные биариловых эфиров, полезные в качестве ингибиторов обратного захвата моноамина
BR9810829A (pt) Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
HUP0300616A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
EA200601852A1 (ru) Тетрагидрохинолиновые производные и способ их получения
MY114679A (en) Aroyl-piperidine derivatives
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
DE60022504D1 (de) Phenoxypropylamin-derivate
NO20054206L (no) Bifenylderivater
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
AR053790A1 (es) Acidos biariloximetilarencarboxilicos. procesos de obtencion y composiciones farmaceuticas.
NO20023977D0 (no) 8,8A-dihydro-indeno(1,2-D)tiazolderivater med en sulfonamid- eller sulfon substituert i 2-posisjonen, en fremgangsmåte forfremstilling derav og anvendelse som et legemiddel
PT1107744E (pt) Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia
DK1222159T3 (da) Mellemprodukter til fremstilling af et benzofuran- eller benzothiophenderivat, som er nitreret i position 5, og anvendelse heraf
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
MXPA05012096A (es) Derivados de amina ciclica, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.